Influence of menopause on high density lipoprotein-cholesterol and lipids

Journal of Korean Medical Science

Volumn 15, Issue 4, 2000, Pages 380-386

  Kim, Chee Jeong ^a   Kim, Tae Ho ^a   Ryu, Wang Seong ^a   Ryoo, Un Ho ^a  

^a Chung Ang University   (South Korea)

Author keywords

Female; Hormones; Lipids; Lipoproteins; Menopause

Indexed keywords

APOLIPOPROTEIN A; BIOLOGICAL MARKER; CHOLESTEROL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A;

ARTERIOSCLEROSIS; ARTICLE; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTOR;

APOLIPOPROTEINS A; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LIPIDS; LIPOPROTEIN(A); MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS;

EID: 0034242699     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2000.15.4.380     Document Type: Article

References (33)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. Ann Intern Med 1976; 85: 447-52.
2. Knopp RH. The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 1988; 72: 23-30S.
3. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
4. Hallberg L, Svanborg A. Cholestrol, phospholipid and triglycerides in plasma in 50-year-old women. Influence of menopause, body weight, skinfold thickness, weight gain and diet in a random population sample. Acta Med Scand 1967; 181: 185-94.
5. Brown SA, Hutchinson R, Morriset J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communitiies (ARIC) Study. Arterioscler Thromb 1993; 8: 1139-58.
6. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med 1996; 156: 500-4.
7. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gordon DJ, Burt VL, Brown CD, Lippel K. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-8.
8. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 1994; 154: 2349-55.
9. Pansini F, Bonaccorsi G, Calisesi M, Campobasso C, Franze GP, Gilli G, Locorotondo G, Mollica G. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturatis 1993; 17: 181-90.
10. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-5.
11. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-65.
12. Genest J Jr, McNamara JR, Ordovas JM Jenner JL, Silberman SR, Anderson KM, Wilson PW, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792-802.
13. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women Influence of various progestogens and duration of therapy. Arch Intern Med 1996; 156: 1693-700.
14. Rosengren A, Wilhelmsen L, Erikssen E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease. A prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301: 1248-51.
15. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994; 14: 275-81.
16. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995; 92: 5-8.
17. Li Z, McNamara JR, Fruchart J, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 1996; 37: 1886-96.
18. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-6.
19. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
20. Walch BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effect of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-204.
21. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women JAMA 1995; 273: 199-208.
22. Farish E, Fletcher CD, Hart DM, Smith ML. Effects of bilateral oophorectomy on lipoprotein metabolism. Br J Obstet Gynaecol 1990; 97: 78-82.
23. Pansini F, Bergamini C, Bettocchi S Jr, Bassi P, Malfaccini M, Bagni B, Mollica G. Short-term effect of oophorectomy on lipoprotein metabolism. Gynecol Obstet Invest 1984; 18: 134-9.
24. Fukami K, Koike K, Hirota K, Yashikawa H, Miyake A. Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. Maturitas 1995; 22: 193-7.
25. Murai A, Miyahara T, Fujimoto N, Matzuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
26. Zenker G, Koeltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942-5.
27. Gurewich V, Mittleman M. Lipoprotein(a) in coronary heart disease. Is it a risk factor after all? JAMA 1994; 271: 1025-6.
28. Berg K, Leren TP. Unchanged serum lipoprotein(a) concentrations with lovastatin [Letter]. Lancet 1989; 2(8666): 812.
29. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 1982; 44: 61-71.
30. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57: 293-301.
31. Meilahn EN, Kuller LH, Matthews KA, Stein EA. Lp(a) concentrations among pre- and postmenopausal women over time: The Healthy Women Study. Circulation 1991; 84(Suppl II): II-546.
32. NIH Consensus Conference. Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. High-density lipoprotein, and coronary heart disease. JAMA 1993; 269: 505-10.
33. Naito HK. Reliability of lipid, lipoprotein, and apolipoprotein measurements. Clin Chem 1988; 34: B84-94.